A novel potential therapy for HSV
Division of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, United StatesNew England Journal of Medicine (Impact Factor: 55.87). 01/2014; 370(3):273-4. DOI: 10.1056/NEJMe1313982
Two medications are licensed in the United States for the treatment of infection with genital herpes simplex virus (HSV): valacyclovir (approved by the Food and Drug Administration in 1995) and famciclovir (approved in 1997). All studied and licensed drugs for HSV infections assessed to date are selective inhibitors of HSV DNA polymerase and act as analogues of nucleoside triphosphate.(1) The report by Wald and colleagues in this issue of the Journal(2) introduces two fundamentally new approaches to the study of medications for the treatment of genital herpes. One approach involves the application of daily quantitative polymerase-chain-reaction (PCR) analysis to define ...
Article: Herpes genitalis[Show abstract] [Hide abstract]
ABSTRACT: Genital herpes is caused by the herpes simplex virus type 1 or 2 and is regarded as one of the most common sexually transmitted infections (STI) and the main cause of genital ulcer disease (GUD) in the developing world. Antiviral treatment with nucleoside analogues offers clinical benefit to symptomatic individuals with first-episode or primary genital herpes as well as for recurrent herpetic episodes.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.